| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 298.85M | 292.98M | 274.42M | 246.78M | 208.06M | 187.13M |
| Gross Profit | 215.89M | 216.69M | 195.13M | 175.98M | 148.21M | 132.81M |
| EBITDA | 28.20M | 32.37M | 24.54M | -9.21M | 1.92M | -834.00K |
| Net Income | 15.11M | 16.96M | 28.52M | -17.87M | -11.81M | -620.00K |
Balance Sheet | ||||||
| Total Assets | 273.05M | 297.92M | 281.44M | 255.00M | 244.27M | 174.09M |
| Cash, Cash Equivalents and Short-Term Investments | 95.98M | 108.91M | 61.03M | 38.06M | 40.71M | 58.56M |
| Total Debt | 42.17M | 45.11M | 50.38M | 72.23M | 83.86M | 21.39M |
| Total Liabilities | 78.12M | 81.33M | 87.80M | 133.60M | 116.04M | 49.34M |
| Stockholders Equity | 194.93M | 216.60M | 193.64M | 121.40M | 128.23M | 124.75M |
Cash Flow | ||||||
| Free Cash Flow | 39.55M | 38.15M | 33.37M | 3.29M | 276.00K | 503.00K |
| Operating Cash Flow | 41.76M | 40.66M | 35.85M | 5.21M | 2.63M | 2.79M |
| Investing Cash Flow | -2.27M | -2.50M | -2.48M | -1.91M | -82.18M | 20.18M |
| Financing Cash Flow | -31.58M | -4.82M | 5.73M | -9.60M | 59.93M | 2.11M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $351.55M | 25.33 | 7.64% | ― | 6.15% | -54.24% | |
| ― | $254.82M | 19.39 | 10.79% | ― | 17.11% | 45.34% | |
| ― | $417.97M | ― | ― | ― | ― | ― | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $232.82M | ― | -87.65% | ― | 2.47% | 56.93% | |
| ― | $236.37M | ― | ― | ― | 45.50% | 53.07% | |
| ― | $247.96M | ― | ― | ― | 57.43% | -155.29% |
Tactile Systems Technology’s recent earnings call presented a mixed sentiment, highlighting strong positive achievements alongside notable financial challenges. The company delivered a solid Q2 performance with significant revenue growth, particularly in the airway clearance segment, and improved gross margins. However, these positives were tempered by a decline in adjusted EBITDA, limited growth in lymphedema revenue, and a cautious approach to full-year guidance increases.
Tactile Systems Technology, Inc., operating as Tactile Medical, is a medical technology company specializing in developing and marketing at-home therapies for chronic conditions such as lymphedema, lipedema, and chronic venous insufficiency, aiming to improve patient care and reduce healthcare costs.